Simulect Inj (basiliximab, Novartis Korea), which is used as an induction therapy to prevent immune rejection in organ transplant patients, is expected to run out of supply in Korea due to issues in securing the supply the drug’s active pharmaceutical ingredient.

In particular, there is no alternative drug for liver transplantation, increasing the need for the government’s prompt response.

Novartis Korea reported to the Ministry of Food and Drug Safety on the 8th that the company expects a supply shortage due to the lack of global supply of the API for Simulect Inj.

Due to the API issue, the amount scheduled to be imported in September will not arrive. As a resul